This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.
Drug: Oral Fedratinib
Oral fedratinib administered as directed by treating physician.
Other Name: FEDR
Subjects will be considered if they received TG101348, SAR302503 or Fedratinib as a
participant on a clinical trial prior to 31 Jan 2018.
Subject is eligible for enrollment in an ongoing clinical trial using Fedratinib or has
been treated with Fedratinib after 31 Jan 2018.
Summit, New Jersey, 07901
Celgene Medical Information
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.